Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
About
This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U. S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and career development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of [trainees] as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
The Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) is a federal funding opportunity designed to strengthen infectious disease research capacity at institutions in low- and middle-income countries (LMICs) through collaborative partnerships with U.S. institutions. This program supports research training that addresses major endemic diseases, emerging infectious diseases, neglected tropical diseases, and infections affecting vulnerable populations including those with HIV co-infections. Eligible applicants include HBCUs, Hispanic-serving institutions, tribal governments, Asian American and Native American Pacific Islander-serving institutions, and other specialized institutions. The program funds comprehensive training programs incorporating didactic instruction, mentored research experiences, and career development skills. A unique feature is the optional clinical trial component, allowing trainees to lead independent clinical trials, participate in ancillary trials, or gain research experience in trials led by other investigators. This funding opportunity is ideal for research institutions committed to building infectious disease research expertise in resource-limited settings and preparing researchers to address critical public health challenges in their regions.
Funding Facts
● Applications openDeadline
August 6, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle
Deadline
2026-08-06
Grant Type
federal
Application Cycle
Annual - Deadline August 6, 2026
Best For
U.S. institutions partnering with LMIC institutions; HBCUs; Minority-serving institutions; Research organizations focused on global infectious disease capacity building
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)?
Eligible applicants include U.S. institutions partnering with low- and middle-income country (LMIC) institutions, Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribal governments, Alaska Native and Native Hawaiian serving institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), faith-based and community-based organizations, and eligible federal agencies. Joint applications from U.S. and LMIC institutions are encouraged. For complete eligibility requirements, consult the official Funding Opportunity Announcement.
How much funding does Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) provide?
Specific funding amounts vary by cycle and application. For current funding levels and budget information, visit the official NIH/FIC website or contact the program officer directly, as amounts are not specified in standard announcements.
How do I apply for Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)?
Applications should be submitted through the NIH Grants.gov system as joint applications from U.S. and LMIC institutions. Your application must propose a collaborative training program with didactic components, mentored research experiences, and career development skills training. If including a clinical trial component, specify whether trainees will lead an independent trial, participate in an ancillary trial, or gain experience in a trial led by another investigator. Review the official Funding Opportunity Announcement on the NIH/FIC website for detailed instructions, required forms, and submission guidelines.
What can Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) funding be used for?
Funding supports research training programs focused on infectious disease research in LMICs. Eligible research areas include prevention, treatment, and public health approaches to basic science, epidemiology, clinical, behavioral, and social science health research. Programs may address major endemic diseases, emerging infectious diseases, neglected tropical diseases, co-infections in HIV-positive individuals, and infections associated with non-communicable diseases of public health importance in LMICs. The optional clinical trial component allows support for trainee-led independent clinical trials or participation in clinical trial research experiences.
Last updated: July 5, 2026